By Pierre Bertrand

 

Novartis said the U.S. Food and Drug Administration has approved its drug Cosentyx for the treatment of the hidradenitis suppurativa skin condition.

Novartis said late Tuesday that the approval of the drug is the first of a new biologic treatment option for the condition in nearly a decade.

The regulator's approval was based on data compiled in the Sunshine and Sunrise Phase 3 study program, Novartis said.

Hidradenitis suppurativa is a chronic and systemic skin disease which causes boil-like bumps that can burst and cause scarring, the company said.

Novartis said there has previously only been one other treatment option for the condition.

 

Write to Pierre Bertrand at pierre.bertrand@wsj.com

 

(END) Dow Jones Newswires

November 01, 2023 02:28 ET (06:28 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Jan 2024 até Fev 2024 Click aqui para mais gráficos Novartis.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Fev 2023 até Fev 2024 Click aqui para mais gráficos Novartis.